Step 1: Understanding the Question:
The question tests the mechanism of action of common oral hypoglycemic drugs, and specifically asks which one does not work by stimulating insulin release from the pancreas.
Step 2: Key Concept or Approach:
Insulin secretagogues act on pancreatic beta cells: sulfonylureas and meglitinides bind the sulfonylurea receptor on the beta-cell ATP-sensitive potassium channel, close the channel, depolarise the cell, and trigger calcium-dependent insulin release. Thiazolidinediones (glitazones) work by a completely different mechanism - they activate PPAR-gamma receptors mainly in adipose tissue and improve peripheral insulin sensitivity, without directly making the pancreas secrete more insulin.
Step 3: Working Through the Options:
Gliclazide and glimepiride are both sulfonylureas, and repaglinide is a meglitinide - all three are classic insulin secretagogues that close beta-cell potassium channels. Rosiglitazone is a thiazolidinedione and is an insulin sensitizer, not a secretagogue.
Step 4: Conclusion:
The correct answer is Rosiglitazone, since it lowers blood glucose by improving insulin sensitivity rather than by stimulating insulin secretion.